Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13865933 | 0.87 | HPGD (0.49) | HPGDALDH1A1HTTTSHRTYK2 | |
| SCHEMBL13865874 | 0.84 | KHK (0.62) | HPGDALDH1A1HTTTSHRTP53 | |
| SCHEMBL13865825 | 0.84 | PDE9A (0.50) | HPGDALDH1A1HTTTSHR | |
| SCHEMBL4512344 | 0.83 | TYK2 (0.48) | HPGDALDH1A1HTTTSHRTYK2 | |
| SCHEMBL13865845 | 0.83 | HPGD (0.54) | HPGDALDH1A1HTTTSHRTYK2 | |
| SCHEMBL13865839 | 0.82 | TYK2 (0.52) | HPGDALDH1A1HTTTSHRTYK2 | |
| SCHEMBL4510202 | 0.80 | TYK2 (0.58) | HPGDALDH1A1HTTTSHRTYK2 | |
| SCHEMBL4511043 | 0.78 | TYK2 (0.46) | HPGDALDH1A1HTTTSHRTYK2 | |
| SCHEMBL13865803 | 0.76 | PDE9A (0.47) | HPGDMAPT | |
| SCHEMBL4516124 | 0.76 | TYK2 (0.54) | HPGDALDH1A1HTTTSHRTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | GALAPAGOS NV (BE) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137549-A1 | Novel compounds useful for the treatment of degenerative & inflamatory diseases | PDE4A, PDE7B, PDE4B | HPGD 132/4885ALDH1A1 240/4885HTT 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.